How does GNGB.Y's PE Ratio compare to its peers?

GNGB.Y is good value based on its Price-To-Earnings Ratio (27.8x) compared to the peer average (53.4x).

How does GNGB.Y's PE Ratio compare vs other companies in the US Medical Equipment Industry?

GNGB.Y is good value based on its Price-To-Earnings Ratio (27.8x) compared to the US Medical Equipment industry average (37.2x).

What is GNGB.Y's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GNGB.Y is good value based on its Price-To-Earnings Ratio (27.8x) compared to the estimated Fair Price-To-Earnings Ratio (33.4x).

What is the Fair Price of GNGB.Y when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

GNGB.Y ($15.76) is trading below our estimate of [[fair value]] ($33.43)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Getinge (OTCPK:GNGB.Y) - Stock Price, News & Analysis

GNGB.Y Stock Overview

Provides products and solutions for operating rooms, intensive-care units, and sterilization departments. More details

GNGB.Y fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	2/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 52.9% below our estimate of its fair value

Earnings are forecast to grow 22.02% per year

Trading at good value compared to peers and industry

Risk Analysis

Unstable dividend track record

Profit margins (5%) are lower than last year (7.4%)

Getinge AB (publ) Competitors

Integer Holdings

NYSE:ITGR

US$4.5b

LivaNova

NasdaqGS:LIVN

US$2.8b

Teleflex

NYSE:TFX

US$8.9b

CONMED

NYSE:CNMD

US$2.2b

Price History & Performance

Summary of all time highs, changes and price drops for Getinge
Historical stock prices
Current Share Price	SEK 15.76
52 Week High	SEK 22.85
52 Week Low	SEK 15.62
Beta	0.49
11 Month Change	-16.53%
3 Month Change	-20.36%
1 Year Change	-25.24%
33 Year Change	-65.19%
5 Year Change	-9.43%
Change since IPO	-58.53%

Recent updates

Shareholder Returns

	GNGB.Y	US Medical Equipment	US Market
7D	-10.3%	-0.7%	-2.1%
1Y	-25.2%	22.5%	29.7%

Return vs Industry: GNGB.Y underperformed the US Medical Equipment industry which returned 22.4% over the past year.

Return vs Market: GNGB.Y underperformed the US Market which returned 29.6% over the past year.

Price Volatility

Is GNGB.Y's price volatile compared to industry and market?
GNGB.Y volatility
GNGB.Y Average Weekly Movement	3.8%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: GNGB.Y has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: GNGB.Y's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1904	11,848	Mattias Perjos	www.getinge.com

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, mechanical circulatory support, advanced patient monitoring, ICU infrastructure equipment, patient flow management, and drainage solutions.

Getinge AB (publ) Fundamentals Summary

How do Getinge's earnings and revenue compare to its market cap?
GNGB.Y fundamental statistics
Market cap	US$4.28b
Earnings (TTM)	US$153.88m
Revenue (TTM)	US$3.06b

27.8x

P/E Ratio

1.4x

P/S Ratio

Is GNGB.Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNGB.Y income statement (TTM)
Revenue	SEK 33.59b
Cost of Revenue	SEK 18.21b
Gross Profit	SEK 15.39b
Other Expenses	SEK 13.69b
Earnings	SEK 1.69b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 28, 2025

Earnings per share (EPS)	6.21
Gross Margin	45.80%
Net Profit Margin	5.03%
Debt/Equity Ratio	30.0%

How did GNGB.Y perform over the long term?

See historical performance and comparison

Dividends

2.5%

Current Dividend Yield

71%

Payout Ratio

GNGB.Y Stock Overview

Rewards

Risk Analysis

Getinge AB (publ) Competitors

NYSE:ITGR

US$4.5b

NasdaqGS:LIVN

US$2.8b

NYSE:TFX

US$8.9b

NYSE:CNMD

US$2.2b

Price History & Performance

Recent News & Updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Recent updates

Getinge Appoints Alexandra Holland Executive Vice President of Communications, Effective November 11, 2024

Getinge AB (publ) (OM:GETI B) completed the acquisition of Paragonix Technologies, Inc. from Signet Healthcare Partners.

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire Paragonix Technologies, Inc. from Signet Healthcare Partners for approximately $480 million.

Getinge AB (publ) to Report Q2, 2024 Results on Jul 18, 2024

Getinge AB (publ) Declares A Dividend, Payable on 29 April 2024

Getinge AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Getinge AB (publ) to Report Fiscal Year 2023 Final Results on Mar 27, 2024

Getinge AB (Publ) Proposes Dividend, Payable on April 29, 2024

Getinge Takes A Leap Forward in Cardiovascular Surgery with the 510(k) Clearance for Vasoview Hemopro 3

Getinge AB (Publ) Provides Sales Guidance for the Year 2024

Getinge Announces CFO Changes

Getinge AB (publ) (OM:GETI B) acquired Healthmark Industries Company, Inc. for $320 million.

Getinge AB (Publ) Announces Resignation of Jeanette Hedén Carlsson as Executive Vice President Brand & Communication, Effective December 31, 2023

Getinge Receives US FDA 510(K) Clearance for Servo-Air® Lite

Getinge AB (publ) (OM:GETI B) entered into an agreement to acquire High Purity New England Inc. for approximately $290 million.

Getinge Provides Financial Guidance for the First Half, Second Half and Full Year of 2023

Getinge AB (Publ) Proposes Dividend

U.S. Food and Drug Administration Broadens the Consent Decree with Getinge and Includes Its Subsidiary Datascope

Getinge AB (publ) Provides Sales Guidance for the Full Year 2022

Getinge AB (Publ) Announces Executive Changes

Getinge AB (Publ) Appoints Joanna Engelke as New Executive Vice President Quality Compliance, Regulatory & Medical Affairs and Member of the Getinge Executive Team

Getinge AB (Publ) Announces Medical Device Field Action of Hls Set Advanced Products

Getinge Appoints Agneta Palmér as Executive Vice President Operational Services Member of the Getinge Executive Team

Getinge AB (publ) to Report Q2, 2022 Results on Jul 19, 2022

Lena Hagman to Leave Getinge AB (publ) as Executive Vice President Quality Compliance, Regulatory & Medical Affairs

Getinge Revises Net Sales Guidance for the Full Year 2022

Getinge AB (publ) Declares Dividend for 2021, Payable on May 3, 2022

Getinge AB (publ) to Report Q1, 2022 Results on Apr 26, 2022

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB to Report Q4, 2022 Results on Feb 01, 2023

Getinge AB (OM:GETI B) acquired Talis Clinical, LLC for approximately SEK 600 million.

Getinge AB Provides Sales Guidance for the Year 2021

Getinge's New Torin Artificial Intelligence Solution Improves Hospital Efficiency

Getinge AB Proposes Dividend, Payable on April 27, 2021

Getinge AB and University of Gothenburg Initiates Strategic Research Partnership

Getinge AB Proposes Executive Changes

Getinge Is Announcing A Recall of HLS Set Advanced Products

Getinge AB Provides No Guidance for the Fourth Quarter of 2020 and for Year 2021

Getinge Not to Present Outlook for the Full Year 2020

Getinge Announces Ventilation Technology for Both Premature Babies and Adults

Getinge AB to Report Q3, 2020 Results on Oct 16, 2020

Getinge Announces Voluntary Recall of the Servo-i Ventilator System's Nebulizer Connector

Getinge AB Appoints Anna Romberg as Executive Vice President Legal, Compliance & Governance and Member, with Effect from October 01, 2020